Skip to content
  • Clinical Studies
  • Pharma SOP’s
  • Pharma tips
  • Pharma Books
  • Stability Studies
  • Schedule M

Pharma GMP

Your Gateway to GMP Compliance and Pharmaceutical Excellence

  • Home
  • Quick Guide
  • Toggle search form

PIC/S Membership: Countries and Agencies Involved

Posted on June 13, 2025 By digi

PIC/S Membership: Countries and Agencies Involved

Global Reach of PIC/S: Member Countries and Regulatory Agencies Involved

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) is a premier international platform that fosters harmonized Good Manufacturing Practice (GMP) inspections across regulatory authorities. Its strength lies in its diverse, global membership of competent authorities committed to cooperation, mutual trust, and standardization. This article offers a comprehensive overview of PIC/S membership and the countries and agencies involved, highlighting its impact on pharmaceutical inspection practices and global GMP alignment.

What is PIC/S and Why Membership Matters?

  • PIC/S is a non-binding cooperative arrangement between pharmaceutical regulatory authorities
  • Its goal is to harmonize GMP inspection standards and foster mutual recognition of inspections
  • Members follow common inspection procedures, use shared tools, and participate in joint training
  • Membership enhances regulatory capacity and enables global reliance frameworks

How Does a Regulatory Authority Join PIC/S?

  • Authorities must demonstrate that their GMP inspection system aligns with PIC/S expectations
  • An on-site assessment is conducted by experienced inspectors from other member countries
  • The evaluation includes:
    • Inspector competency
    • Legal basis for enforcement
    • Inspection planning and documentation
    • CAPA and follow-up mechanisms
  • Successful applicants become official PIC/S Participating Authorities
Also Read:  US FDA EIR (Establishment Inspection Report) Explained

Current PIC/S Member Agencies (as of 2024)

There are more than 50 regulatory authorities across all continents in PIC/S. Some key members include:

  • Europe:
    • EMA (European Medicines Agency)
    • ANSM (France)
    • BfArM (Germany)
    • MHRA (United Kingdom)
    • AIFA (Italy)
    • IGJ (Netherlands)
    • Swissmedic (Switzerland)
    • FAMHP (Belgium)
  • North America:
    • US FDA
    • Health Canada
  • Asia:
    • PMDA (Japan)
    • HSA (Singapore)
    • KFDA (South Korea)
    • NPRA (Malaysia)
    • TFDA (Chinese Taipei)
  • Latin America:
    • ANVISA (Brazil)
    • INVIMA (Colombia)
  • Oceania:
    • TGA (Australia)
    • Medsafe (New Zealand)
  • Africa:
    • SAHPRA (South Africa)

Agencies in Application or Observer Status

  • Several countries are in the process of applying or undergoing assessment
  • Observer status allows authorities to participate in PIC/S meetings and training before full membership
  • Examples include regulatory bodies from India, Indonesia, Egypt, and the Gulf region
Also Read:  FDA Drug Manufacturing Facility Classification Outcomes (NAI, VAI, OAI)

Benefits of PIC/S Membership for Regulatory Agencies

  • Access to shared inspection templates, tools, and training
  • Participation in harmonization working groups and technical committees
  • Global credibility and increased trust in inspection outcomes
  • Opportunity to collaborate on joint or coordinated inspections
  • Facilitates international reliance and reduces inspection duplication

Impact on Industry

  • Manufacturers inspected by a PIC/S member agency may avoid duplicate audits by other member states
  • Helps streamline global GMP compliance through aligned standards and interpretations
  • Encourages adoption of PIC/S inspection formats, such as aide-memoires and inspection report templates
  • Strengthens preparedness for SOP-based inspections and international audits

Regulatory Convergence Through PIC/S

  • PIC/S bridges differences between EU, US, WHO, and regional GMP standards
  • Promotes global convergence through training, mutual confidence, and shared tools
  • Integrates ICH guidelines and WHO technical guidance into member inspection practices
  • Acts as a foundation for future Mutual Recognition Agreements (MRAs)

Joint Inspections Enabled by PIC/S

  • Many PIC/S members collaborate on inspections in third countries
  • EMA and US FDA have performed joint GMP inspections under the PIC/S framework
  • Promotes resource-sharing and unified feedback for global manufacturers
Also Read:  Common Elements Across Global GMP Inspection Systems

How to Stay Updated on PIC/S Membership

  • Visit the official PIC/S website
  • Review the list of current members and application status updates
  • Follow news on inspection reports, joint training sessions, and GMP policy updates
  • Attend PIC/S-linked workshops or regional training events

Conclusion

PIC/S membership offers a gateway to international GMP harmonization and regulatory cooperation. With over 50 authorities spanning every continent, PIC/S creates a trusted network for inspection alignment and knowledge sharing. For regulatory bodies, joining PIC/S represents a commitment to global best practices. For manufacturers, PIC/S member recognition provides a strategic advantage in reducing audit burden and strengthening global compliance. As the scheme continues to grow, it reinforces the principle that quality in pharmaceuticals is truly a shared global responsibility.

International GMP Inspection Standards and Harmonization, PIC/S Role in Harmonized Inspections Tags:global GMP agencies, global inspection alignment, GMP harmonization countries, international GMP membership, international GMP oversight, mutual recognition GMP, PIC/S compliance map, PIC/S FDA EMA WHO, PIC/S inspectorates, PIC/S member countries, PIC/S membership list, PIC/S participating authorities, PIC/S pharmaceutical inspection, PIC/S regulatory network, regulators in PIC/S

Post navigation

Previous Post: Introduction to the Pharmaceutical Inspection Co-operation Scheme (PIC/S)
Next Post: Avoid Water Stagnation in GMP Drains and Sinks to Prevent Contamination

Menu

  • GMP Basics
    • Introduction to GMP
    • What is cGMP?
    • Key Principles of GMP
    • Benefits of GMP in Pharmaceuticals
    • GMP vs. GxP (Good Practices)
  • Regulatory Agencies & Guidelines
    • WHO GMP Guidelines
    • FDA GMP Guidelines
    • MHRA GMP Guidelines
    • SCHEDULE – M – Revised
    • TGA GMP Guidelines
    • Health Canada GMP Regulations
    • NMPA GMP Guidelines
    • PMDA GMP Guidelines
    • EMA GMP Guidelines
  • GMP Compliance & Audits
    • How to Achieve GMP Certification
    • GMP Auditing Process
    • Preparing for GMP Inspections
    • Common GMP Violations
    • Role of Quality Assurance
  • Quality Management Systems (QMS)
    • Building a Pharmaceutical QMS
    • Implementing QMS in Pharma Manufacturing
    • CAPA (Corrective and Preventive Actions) for GMP
    • QMS Software for Pharma
    • Importance of Documentation in QMS
    • Integrating GMP with QMS
  • Pharmaceutical Manufacturing
    • GMP in Drug Manufacturing
    • GMP for Biopharmaceuticals
    • GMP for Sterile Products
    • GMP for Packaging and Labeling
    • Equipment and Facility Requirements under GMP
    • Validation and Qualification Processes in GMP
  • GMP Best Practices
    • Total Quality Management (TQM) in GMP
    • Continuous Improvement in GMP
    • Preventing Cross-Contamination in Pharma
    • GMP in Supply Chain Management
    • Lean Manufacturing and GMP
    • Risk Management in GMP
  • Regulatory Compliance in Different Regions
    • GMP in North America (FDA, Health Canada)
    • GMP in Europe (EMA, MHRA)
    • GMP in Asia (PMDA, NMPA, KFDA)
    • GMP in Emerging Markets (GCC, Latin America, Africa)
    • GMP in India
  • GMP for Small & Medium Pharma Companies
    • Implementing GMP in Small Pharma Businesses
    • Challenges in GMP Compliance for SMEs
    • Cost-effective GMP Compliance Solutions for Small Pharma Companies
  • GMP in Clinical Trials
    • GMP Compliance for Clinical Trials
    • Role of GMP in Drug Development
    • GMP for Investigational Medicinal Products (IMPs)
  • International GMP Inspection Standards and Harmonization
    • Global GMP Inspection Frameworks
    • WHO Prequalification and Inspection Systems
    • US FDA GMP Inspection Programs
    • EMA and EU GMP Inspection Practices
    • PIC/S Role in Harmonized Inspections
    • Country-Specific Inspection Standards (e.g., UK MHRA, US FDA, TGA)
  • GMP Blog
Widget Image
  • Avoid Water Stagnation in GMP Drains and Sinks to Prevent Contamination

    Avoid Water Stagnation in GMP… Read more

International GMP Inspection Standards and Harmonization

  • Global GMP Inspection Frameworks
  • WHO Prequalification and Inspection Systems
  • US FDA GMP Inspection Programs
  • EMA and EU GMP Inspection Practices
  • PIC/S Role in Harmonized Inspections
  • Country-Specific Inspection Standards (e.g., UK MHRA, US FDA, TGA)

International GMP Inspection Standards and Harmonization, PIC/S Role in Harmonized Inspections

  • How PIC/S Enhances GMP Harmonization Across Borders
  • Objectives and Scope of PIC/S in Global GMP
  • PIC/S Membership: Countries and Agencies Involved
  • Introduction to the Pharmaceutical Inspection Co-operation Scheme (PIC/S)
  • EMA’s Harmonization with WHO PQP and PIC/S
  • EMA GMP Inspection Templates and Tools
  • EMA GMP in Advanced Therapy Medicinal Products (ATMPs)
  • Brexit Impact on UK-EU GMP Inspection Alignment
  • GMP Compliance of Importers and Distributors in the EU
  • EudraLex Volume 4 vs. US FDA 21 CFR: Key Differences in GMP Regulations

Copyright © 2025 Pharma GMP.

Powered by PressBook WordPress theme